Peter Marks on Covid-19 vaccine efficacy, EUAs and challenge trials

Michael Mezher

A week after the FDA issued guidance on vaccines to prevent Covid-19, Peter Marks, director of the Center for Biologics Evaluation and Research, shed light …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Peter Marks on Covid-19 vaccine efficacy, EUAs and challenge trials

Michael Mezher

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Are programs with compounded GLP-1s safe for your population?

Pe­ter Marks on Covid-19 vac­cine ef­fi­ca­cy, EUAs and chal­lenge tri­als

Michael Mezher

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Peter Marks on Covid-19 vaccine efficacy, EUAs and challenge trials

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Are programs with compounded GLP-1s safe for your population?